DDInter1696 DDInter927
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Solifenacin {u} (Compound) resembles {v} (Compound) Mequitazine
Solifenacin {u} (Compound) resembles {v} (Compound) Benazepril
Solifenacin {u} (Compound) binds {v} (Gene) CHRM4
Solifenacin {u} (Compound) palliates {v} (Disease) multiple sclerosis
Solifenacin {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Muscarinic Antagonists
Solifenacin {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Solifenacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Solifenacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troglitazone
Solifenacin {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Solifenacin (Compound) resembles Mequitazine (Compound)
Solifenacin (Compound) resembles Benazepril (Compound)
Solifenacin (Compound) binds CHRM4 (Gene)
Solifenacin (Compound) palliates multiple sclerosis (Disease)
Solifenacin (Compound) is included by Cholinergic Muscarinic Antagonists (Pharmacologic Class)
Solifenacin (Compound) causes Atrial fibrillation (Side Effect)
Solifenacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Solifenacin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone
Solifenacin may lead to a major life threatening interaction when taken with Potassium chloride